Keywords: prezista, achieves, non-inferior, virologic, response, lopinavir, 96-week
Prezista achieves non-inferior virologic response to lopinavir
Article | 03 November 2008
96-week results presented from a Phase III, randomized, open-label, ongoing clinical trial showed that 79% of treatment-naive HIV-1 infected adults taking ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
